[Claim 1]

A method for producing an insulin-producing cell population or a pancreatic β cell population, comprising the step of

treating an insulin-producing cell population or a pancreatic β cell population as a starting processing object with an FGFR1 inhibitor in vitro

wherein the insulin-producing cell population comprises insulin-producing cells at a proportion of 5% or more and insulin-producing cells expressing insulin and NKX6.1.

[Claim 2]

The method according to claim 1, further comprising the step of differentiating the insulin-producing cell population treated with the FGFR1 inhibitor.

[Claim 3]

The method according to claim 1 or 2, wherein the insulin-producing cell population or the pancreatic β cell population is treated with less than 5 μM of the FGFR1 inhibitor.

[Claim 4]

The method according to any one of claims 1 to 3, wherein the produced cell population comprises Ki67-positive cells at a proportion of less than 3%.

[Claim 5]

The method according to any one of claims 1 to 4, wherein the FGFR1 inhibitor is 1-[2-amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl]-3-tert-butylurea or a salt thereof.

[Claim 6]

A method for decreasing the number of or inhibiting the proliferation of Ki67-positive cells present in a population of insulin-producing cells or cells at a later stage of differentiation, comprising

treating the cell population as a starting processing object with an FGFR1 inhibitor in vitro,
wherein the insulin-producing cell population comprises insulin-producing cells at a proportion of 5% or more and insulin-producing cells expressing insulin and NKX6.1.

[Claim 7]

The method according to claim 6, wherein the population of insulin-producing cells or cells at a later stage of differentiation is an insulin-producing cell population.

[Claim 8]

The method according to claim 6 or 7, wherein the population of insulin-producing cells or cells at a later stage of differentiation is treated with less than 5 μM of the FGFR1 inhibitor.

[Claim 9]

The method according to any one of claims 6 to 8, wherein the FGFR1 inhibitor is 1-[2-amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl]-3-tert-butylurea or a salt thereof.